Relief Therapeutics Holding AG (RLFTF)

[Narbooty1]

The trial, despite it's size, reached a statistically significant reduction in hospital stay with a p value of 0.043. Obviously a larger size is better, but a p value less that 0.05 is the standard used for statistical significance and generally the standard used by the fda. It doesn't matter how large the study is. That is the purpose of the statistical analysis: to determine the likelyhood that a given result is a direct result of an intervention vs chance for a given population size(n). It doesn't matter if endpoint is labeled a primary or a secondary endpoint ultimately if the the result is statistically significant.

The other major thing to think about here that I haven't seen mentioned is that this trial was done on top of standard of care(which includes steroids and Remdesivir). This statistically significant improvement was IN ADDITION to any benefits from those treatments.

If this drug does not receive EUA I will be surprised, and it will likely be because of some information that we don't actually have access too.

I'm an internal medicine physician who works as a hospitalist in the northeast and has seen(and still sees) more than my share of covid-19 patients on both the general medical floor and in the ICU. Assuming there are no surprises (that is the big question, what else will the trial results show?), I'm excited by the results I have seen so far from this drug.